Poster-Disease-modifying Therapy
October 25, 2021
Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
Background: Subcutaneous interferon ?-1a (sc IFN ?-1a) is a well-established disease-modifying therapy for relapsing multiple sclerosis...
Platform-Disease Modifying Therapies
October 25, 2021
Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-Modifying Drugs: A Systematic Review
Background: It is widely accepted that relapses of multiple sclerosis (MS) decrease during pregnancy; however, studies show an increased...